LabCorp Extends Offer for Orchid for Sixth Time | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today said it has extended its cash tender offer to purchase Orchid Cellmark to 5 p.m. EDT Oct. 7.

The extension is the sixth by LabCorp since it launched its bid for Orchid in April for $2.80 per share, or a total price tag of $85.4 million. The offer had been previously extended to Sept. 9.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CBC Marketplace commissions DNA testing of chicken sandwiches at Subway and other fast-food chains.

In a speech to Congress, President Donald Trump called the drug approval process at FDA "slow and burdensome."

In Genome Research this week: algorithm to tease out strains from metagenomic sequences, drug resistance mechanisms in cancer cells, and more.

Variants in the IFITM3 gene affect inflammatory response to infection, UPI reports.